SubHero Banner

Invokana® (canagliflozin) – New indication

September 27, 2019, Janssen announced the FDA approval of Invokana (canagliflozin), to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus (T2DM) and diabetic nephropathy with albuminuria ˃ 300 mg/day.

Download PDF